revealed that Mn promoted robust type I interferon (IFN) production, leading to safe and significant antitumor immune responses in patients with advanced metastatic solid tumors.[32] The dual activator STING@Mn resulted a significant reduction in the tumor volume compared to ADU‐S100 alone, when measured on day 8 after IT administration twice a week (1.2‐fold; p = 0.0379, Figure1A). This evidence concerns the gene IFNA1 and neoplasm.